Guggenheim Maintains Buy on InflaRx, Raises Price Target to $22
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Guggenheim analyst Yatin Suneja maintains InflaRx (NASDAQ:IFRX) with a Buy and raises the price target from $10 to $22.
Guggenheim analyst Yatin Suneja maintains InflaRx (NASDAQ:IFRX) with a Buy and raises the price target from $10 to $22.